Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 32,393 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 32,393 shares of the stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total value of $352,759.77. Following the completion of the transaction, the chief executive officer now owns 5,940,391 shares of the company’s stock, valued at $64,690,857.99. This represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Patrick Miles also recently made the following trade(s):

• On Wednesday, February 5th, Patrick Miles sold 43,459 shares of Alphatec stock. The shares were sold at an average price of $11.95, for a total value of $519,335.05.
• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The shares were sold at an average price of $12.03, for a total value of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Trading Up 9.6 %

Shares of Alphatec stock opened at $12.12 on Friday. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $15.01. The stock has a 50 day moving average price of $10.57 and a two-hundred day moving average price of $8.35. The stock has a market capitalization of $1.72 billion, a PE ratio of -9.47 and a beta of 1.43.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ATEC. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday. Piper Sandler lifted their target price on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Finally, Barclays lifted their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.67.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATEC. R Squared Ltd purchased a new position in shares of Alphatec during the fourth quarter valued at approximately $29,000. Comerica Bank boosted its position in shares of Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after buying an additional 1,248 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares during the last quarter. Quarry LP boosted its position in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after buying an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC purchased a new position in shares of Alphatec during the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.